Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine for IPL-induced Erythema in Facial Telangiectasias
NCT02761174Phase 4Completed
- Start
- Mar 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of brimonidine in telangiectasia (2 arms). Primary endpoints: Reduction in erythema at 10 weeks and Reduction in oedema at 10 weeks. Started Mar 2016; status: completed.
02
Drugs
brimonidine
03
Conditions
telangiectasia
Beyond the preview
Go deeper on NCT02761174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761174.